TD Cowen lowered the firm’s price target on GoodRx (GDRX) to $6 from $7 and keeps a Buy rating on the shares. The firm said some new offerings show promise and company’s role in Cigna’s new PBM model is potential positive, but material impact unlikely until at least 2027. That said, valuation overly discounts the weaker near-term outlook.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- Trump Weekly: China to suspend some controls on rare earths
- Trump Trade: Nvidia says no active talks on selling Blackwell chip to China
- GoodRx will not partner with TrumpRx, CBS News reports
- GoodRx Holdings: Balancing Challenges and Opportunities Amidst PTR Growth Concerns and Pharma Manufacturing Strength
- GoodRx price target lowered to $4 from $4.25 at UBS